How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.
World J Gastroenterol
; 27(11): 1022-1042, 2021 Mar 21.
Article
in English
| MEDLINE | ID: covidwho-1156170
ABSTRACT
Managing inflammatory bowel disease (IBD) during the coronavirus disease 2019 (COVID-19) pandemic has been a challenge faced by clinicians and their patients, especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly contagious new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2). The knowledge about the impact of this virus on patients with IBD, although it is still scarce, is rapidly evolving. In particular, concerns surrounding medications' impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19, and potentially exacerbate viral replication and the COVID-19 course, are a current thinking of both practicing clinicians and providers caring for patients with IBD. Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19. In this review, we summarize the current data regarding gastrointestinal involvement by SARS-CoV-2 and pharmacologic and surgical management for IBD concerning this infection, and the COVID-19 impact on both the patient's psychological functioning and endoscopy services, and we concisely summarize the telemedicine roles during the COVID-19 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
Inflammatory Bowel Diseases
/
Telemedicine
/
COVID-19
/
Glucocorticoids
/
Immunosuppressive Agents
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
World J Gastroenterol
Journal subject:
Gastroenterology
Year:
2021
Document Type:
Article
Affiliation country:
Wjg.v27.i11.1022
Similar
MEDLINE
...
LILACS
LIS